Our Commitment
As a portfolio company of Paragon Biosciences, Emalex is unceasing in its pursuit to improve the lives of people living with central nervous system (CNS) disorders through meaningful scientific breakthroughs.
Leadership
Our leadership team is comprised of remarkable professionals who are passionate about innovative solutions that improve the lives of people living with chronic central nervous system conditions.
Eric Messner
CEO
Frederick Munschauer, M.D., MSc., FAAN
Chief Medical Officer, Neurology and
Senior Vice President, Medical and
Scientific Affairs
Paul Reinfelds, J.D., Ph.D.
Senior Vice President of Legal Affairs and General Counsel
Jenny Swalec
Vice President, Regulatory Affairs and Quality Assurance
Doug Frandsen
Corporate Controller
Jay White, Ph.D.
Vice President, Chemistry, Manufacturing and Controls (CMC)
Sarah Atkinson, M.D.
Vice President, Clinical Development
George Karkanias, Ph.D., MBA, MSc.
Vice President, Global Head of Medical and Scientific Affairs
Trish Rice
Vice President, Biostatistics and Data Management
Jose (Jesse) Zapata
Associate Vice President, Quality Assurance
David Kim
Senior Director, Clinical Operations
Meredith M. Miller
Senior Director, Clinical Operations
Joy Schleyer
Senior Director, Clinical Operations
Christine H. Soulje, Ph.D.
Senior Director, Product Development
Tom Stothoff
Senior Director, Chemistry, Manufacturing and Controls (CMC) Regulatory Affairs